What do the current NCCN guidelines recommend for metastatic hormone-sensitive (castration-sensitive) prostate...

NCCN Guidelines for Metastatic Hormone-Sensitive Prostate Cancer

I'll walk you through what the current NCCN Guidelines recommend for your situation, explaining the clinical reasoning behind these recommendations.

---

1) FIRST-LINE SYSTEMIC TREATMENT OPTIONS

The Foundation: Androgen Deprivation Therapy (ADT)

According to the NCCN Guidelines for Patients: Advanced-Stage Prostate Cancer (2024-2026), androgen deprivation therapy (ADT) is the main treatment for metastatic prostate cancer that is still hormone-sensitive (meaning it still responds to testosterone reduction).

How ADT works: ADT reduces testosterone to "castration level"—nearly zero testosterone in the bloodstream. This starves the cancer cells of the hormone they need to grow.

ADT comes in several forms:

• LHRH agonists (like leuprolide/Lupron) - injections that stop the testicles from making testosterone
• LHRH antagonists (like degarelix/Firmagon) - similar mechanism, different drug class
• Surgical castration (orchiectomy) - removal of testicles; permanent but less common today

The Critical Shift: ADT Is No Longer Given Alone

This is important: ADT by itself is rarely the complete treatment anymore. According to NCCN Guidelines, "Adding one or two additional therapies to ADT may help you live longer and with fewer symptoms."

This means your oncologist will likely recommend:

• Doublet therapy = ADT + one additional drug
• Triplet therapy = ADT + two additional drugs

---

2) DOUBLET VS. TRIPLET THERAPY: WHAT'S THE DIFFERENCE?

Doublet Therapy (ADT + One Additional Agent)

The NCCN Guidelines identify these main options to combine with ADT:

A) ADT + Second Hormone Therapy (Newer Anti-Androgens)

These are called "novel," "advanced," or "second-generation" anti-androgens. They work differently than older hormone drugs and are more potent at blocking testosterone's effects on cancer cells.

Options include:

• Abiraterone (Zytiga) - blocks testosterone production
• Enzalutamide (Xtandi) - blocks androgen receptor signaling
• Apalutamide (ARN-509)
• Darolutamide (Nubeqa)

B) ADT + Chemotherapy

• Docetaxel (Taxotere) - a chemotherapy drug that can be given early in treatment for metastatic disease

C) ADT + Radiopharmaceutical

• Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) - a targeted radiation therapy that finds PSMA protein on cancer cells

Triplet Therapy (ADT + Two Additional Agents)

According to NCCN Guidelines, some patients may receive three drugs together—for example:

• ADT + second hormone therapy + docetaxel
• ADT + second hormone therapy + radiopharmaceutical

---

3) DISEASE VOLUME AND RISK: HOW DOCTORS DECIDE

This is crucial: Your disease volume (how much cancer you have) and risk factors guide which combination your doctor recommends.

High-Volume Disease

Definition: Extensive metastases (cancer spread), particularly to visceral organs (liver, lungs) or multiple bone metastases.

NCCN Recommendation: Patients with high-volume metastatic disease typically benefit from more aggressive upfront treatment, often including:

• ADT + docetaxel (chemotherapy)
• ADT + second hormone therapy + docetaxel (triplet)

Why? Chemotherapy works quickly to shrink large tumor burdens and can improve survival in these patients.

Low-Volume Disease

Definition: Limited metastases, usually confined to bones or a few lymph nodes; no visceral involvement.

NCCN Recommendation: Patients with low-volume disease may start with:

• ADT + second hormone therapy (doublet)
• ADT + radiopharmaceutical (Pluvicto)

Why? These patients often have slower-growing disease and may not need the toxicity of chemotherapy upfront.

---

4) DOCETAXEL IN FIRST-LINE TREATMENT

When Is Docetaxel Used?

According to NCCN Guidelines, docetaxel (Taxotere) is a chemotherapy option for:

• Newly diagnosed metastatic hormone-sensitive prostate cancer (especially high-volume disease)
• Patients who can physically tolerate chemotherapy

How It Works

Docetaxel is given as an intravenous infusion (slowly injected into a vein) over about an hour. The typical schedule is:

• Given every 3 weeks
• Total of 6-10 cycles (treatments)
• Combined with a daily steroid medication

What Docetaxel Can Do

According to NCCN Guidelines: "Although docetaxel can't cure prostate cancer, it can help people live longer while reducing pain and other symptoms."

Important Considerations

Docetaxel is not for everyone. Your oncologist will assess whether you can tolerate it based on:

• Overall health and fitness
• Kidney and liver function
• Blood counts
• Other medical conditions

---

5) MOLECULAR TESTING AND BIOMARKERS

What Testing Is Recommended?

According to NCCN Guidelines, biomarker testing should be performed to identify specific genetic changes that might guide treatment selection.

Key Biomarkers for Prostate Cancer

A) BRCA1/BRCA2 and DNA Repair Gene Mutations

• Found in approximately 1 in 4 patients with metastatic hormone-resistant prostate cancer
• If present, these mutations make the cancer sensitive to PARP inhibitors (drugs like olaparib, rucaparib)
• NCCN recommends testing for these mutations

B) PSMA (Prostate-Specific Membrane Antigen)

• A protein on the surface of prostate cancer cells
• Important for determining if you're a candidate for Pluvicto (lutetium Lu 177) radiopharmaceutical therapy
• Requires a PSMA-PET scan to confirm PSMA expression before treatment

C) Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB)

• May predict response to immunotherapy (pembrolizumab/Keytruda)
• Relevant for a small percentage of patients

How Testing Is Done

According to NCCN Guidelines, biomarker testing can be performed on:

• Tissue samples from your prostate biopsy or metastatic tumor
• Liquid biopsies (blood tests that detect circulating tumor DNA)

---

6) RADIOTHERAPY IN METASTATIC DISEASE

Metastasis-Directed Radiation Therapy

According to NCCN Guidelines, radiation therapy plays an emerging role in metastatic prostate cancer, particularly metastasis-directed therapy (MDT).

When It's Used

Metastasis-directed radiation is considered when:

• You have only a few metastases (typically up to 5 or so)
• Metastases are in limited locations (e.g., a few lymph nodes or bone sites)
• You're receiving ADT and/or hormone therapy

How It Works

External beam radiation therapy (EBRT) uses a machine to aim high-energy radiation precisely at cancer sites while trying to avoid healthy tissue.

Goals of Metastasis-Directed Therapy

According to NCCN Guidelines, the aims are to:

• Reduce or delay development of new metastases
• Put off the need for more aggressive treatment
• Give you more time to live

Important Note

Metastasis-directed therapy is not meant to treat widespread metastatic cancer. It targets specific areas where imaging has found cancer. For cancer throughout the body, systemic drugs (chemotherapy, hormone therapy, immunotherapy) are used instead.

Combination Approach

NCCN Guidelines note that "In many cases, ADT hormone therapy and one of the newer (next-generation) hormone therapies are given along with metastasis-directed radiation therapy to improve results."

---

7)